Evidence map›Paper›PMID 39578355›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2024

Xpert MTB/RIF Ultra enables sensitive detection of

J Ross, M J Cummings, B Bakamutumaho, R Tokarz, S Al Jubaer, B Mathema, M R O'Donnell, M H Larsen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Bridging the gap in TB diagnostic strategies between technical sophistication and real-world applicability in low-resource settings.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

J RossDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Columbia University Irving Medical Center, New York City, NY, USA.
M J CummingsDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Columbia University Irving Medical Center, New York City, NY, USA;, Center for Infection and Immunity, Columbia University Mailman School of Public Health, Columbia University, New York City, NY, USA.
B BakamutumahoDepartment of Arbovirology, Emerging and Re-Emerging Infectious Diseases, Uganda Virus Research Institute, Entebbe, Uganda;, Immunizable Diseases Unit, Uganda Virus Research Institute, Entebbe, Uganda.
R TokarzCenter for Infection and Immunity, Columbia University Mailman School of Public Health, Columbia University, New York City, NY, USA.
S Al JubaerDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
B MathemaDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York City, NY, USA.
M R O'DonnellDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Columbia University Irving Medical Center, New York City, NY, USA;, Center for Infection and Immunity, Columbia University Mailman School of Public Health, Columbia University, New York City, NY, USA;, Department of Epidemiology, Columbia University Mailman School of Public Health, New York City, NY, USA.
M H LarsenDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.

Funding

The Columbia University Training Program in Lung ScienceT32HL105323 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Jahar Bhattacharya, Wellington V. Cardoso · 2011 to 2026
$4.7M
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South AfricaR01AI167795 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Max O'Donnell · 2022 to 2026
$2.9M
Subtyping sepsis in Uganda using clinical, pathogen, and host response profilingK23AI163364 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CUMMINGS, MATTHEW JOHN · 2022 to 2025
$733k
Targeted next-generation sequencing to enhance detection and genomic characterization of Mycobacterium tuberculosis and high-impact bacterial pathogens among HIV-infected adults with sepsis in UgandaR21AI143417 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI O'DONNELL, MAX · 2020 to 2021
$468k
NHLBI NIH HHS T32 HL105323NIAID NIH HHS K23 AI163364NIAID NIH HHS R01 AI167795NIAID NIH HHS R21 AI143417
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39578355
PMCPMC12853270

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.